Skip to main content
[Preprint]. 2024 Apr 20:2024.04.16.589592. [Version 1] doi: 10.1101/2024.04.16.589592

Table 3.

Neuropathologic Diagnoses by Contributing Institution

Outcome Columbia
N=105
Emory
N=156
Mayo
N=331
MSSM
N=88
Rush
N=228
NIA Reagan *
 No AD 2 (2%) 21 (13%) NA 4 (5%) 4 (2%)
Low Likelihood 30 (29%) 45 (29%) NA 24 (27%) 78 (34%)
Intermediate Likelihood 20 (19%) 20 (13%) NA 16 (18%) 82 (36%)
High Likelihood 48 (46%) 68 (44%) NA 39 (44%) 64 (28%)
Missing or unknown 5 (5%) 2 (1%) NA 5 (6%) 0
Derived AD outcome
Control 16 (15%) 64 (41%) 58 (18%) 22 (25%) 51 (22%)
AD 66 (63%) 77 (49%) 180 (54%) 52 (59%) 125 (55%)
Other 18 (17%) 13 (8%) 93 (28%) 9 (10%) 52 (23%)
Missing or unknown 5 (5%) 2 (1%) 0 5 (6%) 0
*

NIA Reagan score modified in accordance with Bennett et al, 2006 [63]: No AD: CERAD = No AD/None and Braak = Stage 0; Low Likelihood: CERAD = No AD/None and Braak ≥ Stage I OR CERAD = Possible/sparse and Braak = any stage OR CERAD = Probable AD/moderate and Braak ≤ Stage II; Intermediate Likelihood: CERAD = Probable/moderate and Braak ≥ Stage III OR CERAD = Definite/frequent and Braak ≥ Stage I and ≤ Stage IV; High Likelihood: CERAD = Definite AD/frequent and Braak ≥ Stage V.

For Mayo patients, this outcome is the reported diagnosis according to Mayo neurologist guidelines, as reported [57]. For all other patients: Control: CERAD = No AD/None or Possible/sparse and Braak ≤ Stage III; AD case: CERAD = Probable/moderate or Definite/frequent and Braak ≥ Stage IV; Other = all other combinations of CERAD and Braak.

NA = not applicable for Mayo patients since Mayo did not report CERAD measures